In addition, this study also has limitations: there is a lack of more animal and cell experimental verification, such as gene knockout, animal modeling, etc. In addition, we will strengthen this part of the study in the future to more comprehensively reveal the potential mechanism of OSBPL3 in the treatment of MASLD more comprehensively, and provide more theoretical references for MASLD. This evidence concerns the gene OSBPL3 and metabolic dysfunction-associated steatotic liver disease.